Dr Reddy's Laboratories June Quarter Profit Declines 13% To Rs 579 Crore
Pharmaceuticals major Dr Reddy's Laboratories on Wednesday reported a 12.60 per cent annual decline in its net profit to Rs 579.3 crore in the quarter ended June 30. The drug maker had reported a net profit of Rs 662.8 crore in the corresponding period a year ago. In a regulatory filing, Dr Reddy's Labs said its revenue from operations came in at Rs 4,417.5 crore in the April-June period, marking a rise of 15 per cent compared to the year-ago period.
The Hyderabad-based company's earnings before interest, taxes, depreciation, and amortization (EBITDA) - or operating profit - rose 2 per cent to Rs 1,162 crore. Its gross margin improved to 56 per cent from 51.7 per cent, it said.
Revenue from North America, its biggest market, rose 6 per cent to Rs 1,730 crore driven by contribution from new products launched and aided by a favorable forex rate, which was partially offset by price erosion, Dr Reddy's Labs added.
Revenue from India declined 10 per cent annually to Rs 630 crore. The decline was on account of lower sales volume due to lower prescriptions generated and fall in patient footfalls in pharmacies and clinics due to COVID-19, the company said.
"The current quarter's financial performance has been strong across all parameter. l am glad that we have been able to serve our patients well and ensured continuity of business operations despite the challenging times," said GV Prasad, co-chairman and managing director, Dr Reddy's Laboratories.
"We have started integration and acquired business from Wockhardt and executed two important licencing arrangements for treatment options for COVID-19. Currently, we are working towards bringing both these drugs to multiple markets."
Dr Reddy's said its operations have continued without much impact, as it continued its engagement with doctors through digital channels, ensured regular supplies of our products to meet with the market demand and continued R&D activities including few projects pertaining to COVID-19.
At 1:48 pm, Dr Reddy's Labs shares traded 3 per cent higher at Rs 4,175, outperforming the benchmark Sensex index, which was down 0.45 per cent amid volatile trade.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.